Johnson & Johnson $JNJ Position Raised by TFB Advisors LLC

TFB Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 19.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 2,320 shares of the company’s stock after buying an additional 379 shares during the quarter. TFB Advisors LLC’s holdings in Johnson & Johnson were worth $354,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. Wealth Group Ltd. acquired a new position in Johnson & Johnson in the first quarter worth approximately $218,000. GAMMA Investing LLC grew its position in Johnson & Johnson by 48.0% in the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after buying an additional 14,118 shares during the last quarter. JFS Wealth Advisors LLC grew its position in Johnson & Johnson by 1.7% in the first quarter. JFS Wealth Advisors LLC now owns 30,792 shares of the company’s stock worth $5,107,000 after buying an additional 505 shares during the last quarter. Finally, XML Financial LLC grew its position in Johnson & Johnson by 1.4% in the first quarter. XML Financial LLC now owns 70,496 shares of the company’s stock worth $11,691,000 after buying an additional 959 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research report on Monday. Argus set a $210.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 0.5%

Shares of NYSE:JNJ opened at $192.81 on Thursday. The firm has a fifty day moving average of $181.64 and a two-hundred day moving average of $165.56. The firm has a market capitalization of $464.35 billion, a P/E ratio of 18.61, a price-to-earnings-growth ratio of 2.25 and a beta of 0.40. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.